Senior Vice President, Market Access and Policy Strategy

Lindsay Bealor Greenleaf, JD, MBA

Lindsay leads ADVI’s policy team and guides legislative, regulatory and market access efforts across payers for clients spanning the pharmaceutical, biotechnology, device, diagnostic and digital health industries, as well as physician practices and specialty societies. 

Lindsay is a healthcare policy expert whose background in government affairs and market access gives her foresight into policy changes that will impact her clients. She directs ADVI’s policy and access activities and provides strategic counsel on legislative, regulatory and market access issues pertaining to Medicare, Medicaid, and commercial markets, prescription drug coverage and reimbursement, and provider reimbursement across sites of service. Owing to her expertise, she has become a healthcare policy expert and trusted source for publications such as CNBC, Bloomberg Law, Daily Caller, and Fierce Healthcare.

In her previous work with The McManus Group, Lindsay developed and negotiated legislative solutions with stakeholders, congressional staff, and Members of Congress on behalf of clients spanning the pharmaceutical, biotechnology and medical device industries, physician societies, and employee benefit administrators.

Lindsay earned a JD from the University of Houston Law Center, an MBA from the Bauer College of Business, and a BA from the University of Texas at Austin. Lindsay is licensed to practice law in Texas and Washington, DC.

CEO insights

Real analysis from people who’ve been there

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Inflation Reduction Act Pharmaceuticals and Biotech State Policy

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

On October 4, 2024, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “HHS Notice of …

Brenna Raines, MHA
October 21, 2024

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: CMS Finalizes Guidance on IPAY 2027 Negotiation and MFP Implementation for 2026/27

On October 2, 2024, CMS issued final guidance on the Medicare Drug Price Negotiation Program for IPAY 2027 and Manufacturer …

Lindsay Bealor Greenleaf, JD, MBA
October 11, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases Medicaid Drug Rebate Program Final Rule

On September 20, 2024, the Centers for Medicare and Medicaid Services (CMS) released a Final Rule titled “Misclassification of Drugs, …

Lindsay Bealor Greenleaf, JD, MBA
September 27, 2024

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: CMS Issues MFPs for the First 10 Drugs Selected for Government Negotiation

On August 15, 2024, the Centers for Medicare and Medicaid Services (CMS) announced the Maximum Fair Prices (MFPs) for the …

Lindsay Bealor Greenleaf, JD, MBA
September 3, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases Final Part Two Guidance for the MPPP Program

On July 16, the Centers for Medicare and Medicaid Services (CMS) released the Final Part Two Guidance on the Medicare …

Lindsay Bealor Greenleaf, JD, MBA
August 13, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases the FY 2025 IPPS Final Rule

On August 1, 2024, the Centers for Medicare and Medicaid Services (CMS) released the Fiscal Year (FY) 2025 Hospital Inpatient …

Lindsay Bealor Greenleaf, JD, MBA
August 13, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases 2025 OPPS Proposed Rule

On July 10, 2024, the Centers for Medicare and Medicaid Services (CMS) issued the 2025 Medicare Hospital Outpatient Prospective Payment …

Lindsay Bealor Greenleaf, JD, MBA
July 17, 2024

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.